MA35451B1 - Dérivés de pyrrolopyrimidine et de purine - Google Patents

Dérivés de pyrrolopyrimidine et de purine

Info

Publication number
MA35451B1
MA35451B1 MA36848A MA36848A MA35451B1 MA 35451 B1 MA35451 B1 MA 35451B1 MA 36848 A MA36848 A MA 36848A MA 36848 A MA36848 A MA 36848A MA 35451 B1 MA35451 B1 MA 35451B1
Authority
MA
Morocco
Prior art keywords
pyrrolopyrimidine
purine derivatives
formula
purine
derivatives
Prior art date
Application number
MA36848A
Other languages
English (en)
Inventor
Hengmiao Cheng
Theodore Otto Johnson Jr
John Charles Kath
Kevin Kun-Chin Liu
Elizabeth Ann Lunney
Asako Nagata
Sajiv Krishnan Nair
Simon Paul Planken
Scott Channing Sutton
Original Assignee
Pfizer
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=47116127&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MA35451(B1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Pfizer filed Critical Pfizer
Publication of MA35451B1 publication Critical patent/MA35451B1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D473/00—Heterocyclic compounds containing purine ring systems
    • C07D473/02—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6
    • C07D473/18—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 one oxygen and one nitrogen atom, e.g. guanine
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)

Abstract

L'invention concerne des composés représentés par la formule (i) ou des sels pharmaceutiquement acceptables de ces composés. Dans la formule, q, t, v, w, x, y, z, le cycle a, r
MA36848A 2011-09-22 2014-03-21 Dérivés de pyrrolopyrimidine et de purine MA35451B1 (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201161538103P 2011-09-22 2011-09-22
US201261639639P 2012-04-27 2012-04-27
PCT/IB2012/054702 WO2013042006A1 (fr) 2011-09-22 2012-09-10 Dérivés de pyrrolopyrimidine et de purine

Publications (1)

Publication Number Publication Date
MA35451B1 true MA35451B1 (fr) 2014-09-01

Family

ID=47116127

Family Applications (1)

Application Number Title Priority Date Filing Date
MA36848A MA35451B1 (fr) 2011-09-22 2014-03-21 Dérivés de pyrrolopyrimidine et de purine

Country Status (28)

Country Link
US (2) US9040547B2 (fr)
EP (1) EP2758402B9 (fr)
JP (1) JP5914667B2 (fr)
KR (1) KR20140059246A (fr)
CN (1) CN103814030A (fr)
AP (1) AP2014007475A0 (fr)
AR (1) AR088760A1 (fr)
AU (1) AU2012311184A1 (fr)
BR (1) BR112014006840A2 (fr)
CA (1) CA2847540C (fr)
CL (2) CL2014002726A1 (fr)
CO (1) CO6910196A2 (fr)
CR (1) CR20140132A (fr)
DO (1) DOP2014000055A (fr)
EA (1) EA201490673A1 (fr)
ES (1) ES2575710T3 (fr)
IL (1) IL231592A0 (fr)
MA (1) MA35451B1 (fr)
MD (1) MD20140023A2 (fr)
MX (1) MX2014003501A (fr)
NI (1) NI201400023A (fr)
PE (1) PE20141228A1 (fr)
SG (1) SG2014014450A (fr)
TN (1) TN2014000115A1 (fr)
TW (1) TWI492946B (fr)
UA (1) UA110259C2 (fr)
UY (1) UY34342A (fr)
WO (1) WO2013042006A1 (fr)

Families Citing this family (49)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102105150B (zh) 2008-05-21 2014-03-12 阿里亚德医药股份有限公司 用作激酶抑制剂的磷衍生物
US9273077B2 (en) 2008-05-21 2016-03-01 Ariad Pharmaceuticals, Inc. Phosphorus derivatives as kinase inhibitors
US9290499B2 (en) 2010-05-19 2016-03-22 The University Of North Carolina At Chapel Hill Pyrazolopyrimidine compounds for the treatment of cancer
SG186378A1 (en) * 2010-06-23 2013-01-30 Hanmi Science Co Ltd Novel fused pyrimidine derivatives for inhibition of tyrosine kinase activity
JP5999177B2 (ja) 2011-05-04 2016-09-28 アリアド・ファーマシューティカルズ・インコーポレイテッド Ｅｇｆｒ発動性がんの細胞増殖阻害用化合物
MX2014004086A (es) 2011-10-03 2014-09-22 Univ North Carolina Compuestos de pirrolopirimidina para el tratamiento del cancer.
AU2013204563B2 (en) 2012-05-05 2016-05-19 Takeda Pharmaceutical Company Limited Compounds for inhibiting cell proliferation in EGFR-driven cancers
KR20150018789A (ko) 2012-05-22 2015-02-24 더 유니버시티 오브 노쓰 캐롤라이나 엣 채플 힐 암의 치료를 위한 피리미딘 화합물
WO2014062774A1 (fr) 2012-10-17 2014-04-24 The University Of North Carolina At Chapel Hill Composés pyrazolopyrimidines pour le traitement du cancer
US9771330B2 (en) 2012-11-27 2017-09-26 The University Of North Carolina At Chapel Hill Pyrimidine compounds for the treatment of cancer
MX2015009209A (es) 2013-01-16 2016-03-17 Signal Pharm Llc Compuestos sustituidos de pirrolopirimidina, composiciones de los mismos, y metodos de tratamiento con los mismos.
SG11201506531WA (en) * 2013-03-14 2015-09-29 Pfizer Combination of an egfr t790m inhibitor and an egfr inhibitor for the treatment of non-small cell lung cancer
US9611283B1 (en) 2013-04-10 2017-04-04 Ariad Pharmaceuticals, Inc. Methods for inhibiting cell proliferation in ALK-driven cancers
KR101657616B1 (ko) * 2013-05-24 2016-09-19 주식회사유한양행 피리미딘 고리를 포함하는 바이사이클릭 유도체 및 그의 제조방법
US9840517B2 (en) * 2013-09-18 2017-12-12 Beijing Hanmi Pharmaceutical Co., Ltd. Compound inhibiting activities of BTK and/or JAK3 kinases
CN104513229A (zh) * 2013-09-28 2015-04-15 正大天晴药业集团股份有限公司 喹唑啉衍生物及其制备方法
UA115388C2 (uk) * 2013-11-21 2017-10-25 Пфайзер Інк. 2,6-заміщені пуринові похідні та їх застосування в лікуванні проліферативних захворювань
CA2937430A1 (fr) 2014-01-29 2015-08-06 Glaxosmithkline Intellectual Property Development Limited Composes
PE20161443A1 (es) * 2014-01-29 2017-01-06 Glaxosmithkline Ip Dev Ltd Compuestos
US20170137426A1 (en) * 2014-03-28 2017-05-18 Changzhou Jiekai Pharmatech Co., Ltd. Heterocyclic compounds as axl inhibitors
CA2945129A1 (fr) 2014-04-11 2015-10-15 The University Of North Carolina At Chapel Hill Composes de pyrrolopyrimidine specifiques de mertk
EP3145512B1 (fr) * 2014-05-19 2019-07-17 Jiangsu Hengrui Medicine Co., Ltd. Composés éthynyle hétérobicycliques substitués en tant qu'inhibiteurs de la tyrosine kinase
CN106715427A (zh) * 2014-07-14 2017-05-24 西格诺药品有限公司 利用取代的吡咯并嘧啶化合物、其组合物治疗癌症的方法
NZ629796A (en) * 2014-07-14 2015-12-24 Signal Pharm Llc Amorphous form of 4-((4-(cyclopentyloxy)-5-(2-methylbenzo[d]oxazol-6-yl)-7h-pyrrolo[2,3-d]pyrimidin-2-yl)amino)-3-methoxy-n-methylbenzamide, compositions thereof and methods of their use
CN105524068B (zh) 2014-09-30 2017-11-24 上海海雁医药科技有限公司 氮杂双环衍生物、其制法与医药上的用途
CN111170998B (zh) 2014-11-05 2023-04-11 益方生物科技(上海)股份有限公司 嘧啶或吡啶类化合物、其制备方法和医药用途
CN107406430B (zh) 2015-03-20 2019-04-26 正大天晴药业集团股份有限公司 喹唑啉衍生物的盐及其制备方法
EP3273966B1 (fr) * 2015-03-27 2023-05-03 Dana-Farber Cancer Institute, Inc. Inhibiteurs de kinases cycline-dépendantes
CN106236060B (zh) 2015-06-04 2021-04-09 松下知识产权经营株式会社 生物体信息检测装置
WO2017087905A1 (fr) * 2015-11-20 2017-05-26 Denali Therapeutics Inc. Composés, compositions, et procédés
CN108495563B (zh) * 2015-11-25 2022-04-26 R.J.雷诺兹烟草公司 烟碱盐、共晶体和盐共晶体配合物
US11028080B2 (en) 2016-03-11 2021-06-08 Denali Therapeutics Inc. Substituted pyrimidines as LRKK2 inhibitors
US10709708B2 (en) 2016-03-17 2020-07-14 The University Of North Carolina At Chapel Hill Method of treating cancer with a combination of MER tyrosine kinase inhibitor and an epidermal growth factor receptor (EGFR) inhibitor
HRP20211923T1 (hr) 2016-06-16 2022-03-04 Denali Therapeutics Inc. Pirimidin-2-ilamino-1h-pirazoli kao inhibitori lrrk2 za uporabu u liječenju neurodegenerativnih poremećaja
EP3587422A4 (fr) 2017-02-22 2020-05-06 Daegu-Gyeongbuk Medical Innovation Foundation Composé dérivé de pyrrolo-pyrimidine, son procédé de préparation, et composition pharmaceutique comprenant ledit composé en tant que principe actif pour la prévention ou le traitement d'une maladie liée à la protéine kinase
KR102398659B1 (ko) * 2017-03-17 2022-05-16 주식회사 대웅제약 카이네이즈 저해제로서의 피롤로트리아진 유도체
EP3694528A4 (fr) 2017-10-13 2021-07-28 The Regents of the University of California Modulateurs de mtorc1
SG11202005264PA (en) 2017-12-05 2020-07-29 Oscotec Inc Pyrrolo(pyrazolo)pyrimidine derivative as lrrk2 inhibitor
KR102577241B1 (ko) 2017-12-28 2023-09-11 주식회사 대웅제약 카이네이즈 저해제로서의 아미노-플루오로피페리딘 유도체
KR102577242B1 (ko) * 2017-12-28 2023-09-11 주식회사 대웅제약 카이네이즈 저해제로서의 아미노-메틸피페리딘 유도체
LT3733673T (lt) * 2017-12-28 2022-08-10 Daewoong Pharmaceutical Co., Ltd. Oksi-fluorpiperidino darinys, kaip kinazės inhibitorius
EP3842435A4 (fr) * 2018-09-20 2022-05-11 Hanmi Pharm. Co., Ltd. Nouveau dérivé de sulfonamide présentant un squelette de pyrimidine fusionné, ayant un effet inhibiteur de mutation du récepteur du facteur de croissance épidermique
KR102377007B1 (ko) * 2018-09-20 2022-03-22 한미약품 주식회사 상피세포 성장인자 수용체 돌연변이 저해 효과를 갖는 신규 융합 피리미딘 골격 설폰아마이드 유도체
JP2022522534A (ja) 2019-04-02 2022-04-19 アリゴス セラピューティクス インコーポレイテッド Ｐｒｍｔ５を標的にする化合物
WO2021147952A1 (fr) * 2020-01-21 2021-07-29 江苏先声药业有限公司 Composé pyrimidopyrrole
CN115244055A (zh) * 2020-01-21 2022-10-25 江苏先声药业有限公司 嘧啶并五元环类衍生物及其应用
TW202214643A (zh) * 2020-09-22 2022-04-16 大陸商江蘇先聲藥業有限公司 嘧啶并吡咯類化合物
CN114315838A (zh) * 2020-09-30 2022-04-12 江苏先声药业有限公司 嘧啶并吡咯类化合物
CN118103371A (zh) * 2021-09-18 2024-05-28 山东新时代药业有限公司 一种egfr抑制剂及其制备方法和用途

Family Cites Families (86)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8607683D0 (en) 1986-03-27 1986-04-30 Ici Plc Anti-tumor agents
GB8827305D0 (en) 1988-11-23 1988-12-29 British Bio Technology Compounds
WO1992020642A1 (fr) 1991-05-10 1992-11-26 Rhone-Poulenc Rorer International (Holdings) Inc. Composes aryle et heteroaryle bis monocycliques et/ou bicycliques qui inhibent la tyrosine kinase d'un recepteur du egf et/ou du pdgf
NZ243082A (en) 1991-06-28 1995-02-24 Ici Plc 4-anilino-quinazoline derivatives; pharmaceutical compositions, preparatory processes, and use thereof
US5587458A (en) 1991-10-07 1996-12-24 Aronex Pharmaceuticals, Inc. Anti-erbB-2 antibodies, combinations thereof, and therapeutic and diagnostic uses thereof
AU661533B2 (en) 1992-01-20 1995-07-27 Astrazeneca Ab Quinazoline derivatives
WO1993016185A2 (fr) 1992-02-06 1993-08-19 Creative Biomolecules, Inc. Proteine de liaison biosynthetique pour marqueur de cancer
US6177401B1 (en) 1992-11-13 2001-01-23 Max-Planck-Gesellschaft Zur Forderung Der Wissenschaften Use of organic compounds for the inhibition of Flk-1 mediated vasculogenesis and angiogenesis
GB9323290D0 (en) 1992-12-10 1994-01-05 Zeneca Ltd Quinazoline derivatives
US5455258A (en) 1993-01-06 1995-10-03 Ciba-Geigy Corporation Arylsulfonamido-substituted hydroxamic acids
GB9314884D0 (en) 1993-07-19 1993-09-01 Zeneca Ltd Tricyclic derivatives
GB9314893D0 (en) 1993-07-19 1993-09-01 Zeneca Ltd Quinazoline derivatives
IL112248A0 (en) 1994-01-25 1995-03-30 Warner Lambert Co Tricyclic heteroaromatic compounds and pharmaceutical compositions containing them
GB9510757D0 (en) 1994-09-19 1995-07-19 Wellcome Found Therapeuticaly active compounds
GB9424233D0 (en) 1994-11-30 1995-01-18 Zeneca Ltd Quinazoline derivatives
US5863949A (en) 1995-03-08 1999-01-26 Pfizer Inc Arylsulfonylamino hydroxamic acid derivatives
US5861510A (en) 1995-04-20 1999-01-19 Pfizer Inc Arylsulfonyl hydroxamic acid derivatives as MMP and TNF inhibitors
US5880141A (en) 1995-06-07 1999-03-09 Sugen, Inc. Benzylidene-Z-indoline compounds for the treatment of disease
GB9520822D0 (en) 1995-10-11 1995-12-13 Wellcome Found Therapeutically active compounds
GB9624482D0 (en) 1995-12-18 1997-01-15 Zeneca Phaema S A Chemical compounds
DK0780386T3 (da) 1995-12-20 2003-02-03 Hoffmann La Roche Matrixmetalloproteaseinhibitorer
GB9603095D0 (en) 1996-02-14 1996-04-10 Zeneca Ltd Quinazoline derivatives
NZ331191A (en) 1996-03-05 2000-03-27 Zeneca Ltd 4-anilinoquinazoline derivatives and pharmaceutical compositions thereof
WO1998002434A1 (fr) 1996-07-13 1998-01-22 Glaxo Group Limited Composes heterocycliques condenses en tant qu'inhibiteurs de la proteine tyrosine kinase
DE69718472T2 (de) 1996-07-13 2003-11-06 Glaxo Group Ltd Bicyclische heteroaromatische verbindungen als protein tyrosine kinase inhibitoren
HRP970371A2 (en) 1996-07-13 1998-08-31 Kathryn Jane Smith Heterocyclic compounds
KR20000067904A (ko) 1996-07-18 2000-11-25 디. 제이. 우드, 스피겔 알렌 제이 매트릭스 메탈로프로테아제의 포스피네이트계 억제제
US5866702A (en) * 1996-08-02 1999-02-02 Cv Therapeutics, Incorporation Purine inhibitors of cyclin dependent kinase 2
WO1998007697A1 (fr) 1996-08-23 1998-02-26 Pfizer Inc. Derives de l'acide arylsulfonylamino hydroxamique
ATE272640T1 (de) 1997-01-06 2004-08-15 Pfizer Cyclische sulfonderivate
DK0977733T3 (da) 1997-02-03 2003-11-24 Pfizer Prod Inc Arylsulfonylaminohydroxamsyrederivater
AU5493598A (en) 1997-02-07 1998-08-26 Pfizer Inc. N-hydroxy-beta-sulfonyl-propionamide derivatives and their use as inhibitors of matrix metalloproteinases
YU37499A (sh) 1997-02-11 2002-09-19 Pfizer Inc. Derivati arilsulfonil hidroksamske kiseline
WO1998050356A1 (fr) 1997-05-07 1998-11-12 Sugen, Inc. Derives de 2-indolinone utilises en tant que modulateurs de l'activite de la proteine kinase
EP0984692A4 (fr) 1997-05-30 2001-02-21 Merck & Co Inc Nouveaux inhibiteurs d'angiogenese
EP1005470B1 (fr) 1997-08-22 2007-08-01 AstraZeneca AB Derives d'oxindolylquinazoline utiles comme inhibiteurs d'angiogenese
WO1999016755A1 (fr) 1997-09-26 1999-04-08 Merck & Co., Inc. Nouveaux inhibiteurs de l'angiogenese
CN101328186A (zh) 1997-11-11 2008-12-24 辉瑞产品公司 用作抗癌药的噻吩并嘧啶和噻吩并吡啶衍生物
GB9725782D0 (en) 1997-12-05 1998-02-04 Pfizer Ltd Therapeutic agents
GB9800575D0 (en) 1998-01-12 1998-03-11 Glaxo Group Ltd Heterocyclic compounds
RS49779B (sr) 1998-01-12 2008-06-05 Glaxo Group Limited, Biciklična heteroaromatična jedinjenja kao inhibitori protein tirozin kinaze
GB9801690D0 (en) 1998-01-27 1998-03-25 Pfizer Ltd Therapeutic agents
PA8469401A1 (es) 1998-04-10 2000-05-24 Pfizer Prod Inc Derivados biciclicos del acido hidroxamico
PA8469501A1 (es) 1998-04-10 2000-09-29 Pfizer Prod Inc Hidroxamidas del acido (4-arilsulfonilamino)-tetrahidropiran-4-carboxilico
BR9910792A (pt) 1998-05-29 2002-01-29 Sugen Inc Inibidores de quinase protéica 2-indolinona substituìda com pirrol
UA71945C2 (en) 1999-01-27 2005-01-17 Pfizer Prod Inc Substituted bicyclic derivatives being used as anticancer agents
JP3270834B2 (ja) 1999-01-27 2002-04-02 ファイザー・プロダクツ・インク 抗がん剤として有用なヘテロ芳香族二環式誘導体
UA74142C2 (uk) 1999-02-01 2005-11-15 Сіві Серапьютікс, Інк. ПУРИНОВІ ІНГІБІТОРИ ЦИКЛІНОЗАЛЕЖНОЇ КІНАЗИ 2 ТА Ik-<font face="Symbol">a</font>
CZ20023951A3 (cs) 2000-06-22 2004-01-14 Pfizer Products Inc. Substituované bicyklické deriváty pro léčení abnormálního buničného růstu
EP1317444B1 (fr) 2000-09-15 2006-05-31 Vertex Pharmaceuticals Incorporated Composes pyrazoliques utiles comme inhibiteurs de la proteine kinase
IL156369A0 (en) 2000-12-21 2004-01-04 Vertex Pharma Pyrazole derivatives and pharmaceutical compositions containing the same
GB0101686D0 (en) * 2001-01-23 2001-03-07 Cancer Res Campaign Tech Cyclin dependent kinase inhibitors
AR042586A1 (es) 2001-02-15 2005-06-29 Sugen Inc 3-(4-amidopirrol-2-ilmetiliden)-2-indolinona como inhibidores de la protein quinasa; sus composiciones farmaceuticas; un metodo para la modulacion de la actividad catalitica de la proteinquinasa; un metodo para tratar o prevenir una afeccion relacionada con la proteinquinasa
JP2007526291A (ja) 2004-03-05 2007-09-13 ケンブリッジ・バイオテクノロジー・リミテッド アデノシン受容体アゴニスト
GB0407723D0 (en) * 2004-04-05 2004-05-12 Novartis Ag Organic compounds
DE602005024382D1 (de) 2004-04-13 2010-12-09 Astellas Pharma Inc Polycyclische pyrimidine als kaliumionenkanal-modulatoren
JP5368701B2 (ja) 2004-07-02 2013-12-18 エクセリクシス、インコーポレイテッド ｃ−Ｍｅｔモジュレーター及び使用方法
GB0502573D0 (en) 2005-02-08 2005-03-16 Topotarget As Therapeutic compounds
GB0505219D0 (en) 2005-03-14 2005-04-20 Novartis Ag Organic compounds
GB0604944D0 (en) * 2006-03-11 2006-04-19 Vernalis R&D Ltd Pyrrolopyrimidine compounds
AR064415A1 (es) 2006-12-21 2009-04-01 Cancer Rec Tech Ltd Derivados de pirrolo-piperidinas y purinas,composiciones farmaceuticas que los contienen y usos en trastornos y/o enfermedades mediadas por pka y pkb.
EA200900983A1 (ru) 2007-01-26 2010-02-26 Айрм Ллк Соединения и композиции в качестве ингибиторов киназы
CN101663305A (zh) * 2007-02-06 2010-03-03 辉瑞大药厂 作为hsp-90抑制剂用于治疗癌症的2-氨基-5,7-二氢-6h-吡咯并[3,4-d]嘧啶衍生物
UA99459C2 (en) 2007-05-04 2012-08-27 Астразенека Аб 9-(pyrazol-3-yl)- 9h-purine-2-amine and 3-(pyraz0l-3-yl)-3h-imidazo[4,5-b]pyridin-5-amine derivatives and their use for the treatment of cancer
US9603848B2 (en) 2007-06-08 2017-03-28 Senomyx, Inc. Modulation of chemosensory receptors and ligands associated therewith
US8633186B2 (en) 2007-06-08 2014-01-21 Senomyx Inc. Modulation of chemosensory receptors and ligands associated therewith
US7928111B2 (en) 2007-06-08 2011-04-19 Senomyx, Inc. Compounds including substituted thienopyrimidinone derivatives as ligands for modulating chemosensory receptors
WO2009026107A1 (fr) 2007-08-17 2009-02-26 Portola Pharmaceuticals, Inc. Inhibiteurs de protéine kinases
TW201024298A (en) * 2008-09-23 2010-07-01 Palau Pharma Sa (R)-3-(N,N-dimethylamino)pyrrolidine derivatives
US8426428B2 (en) * 2008-12-05 2013-04-23 Principia Biopharma, Inc. EGFR kinase knockdown via electrophilically enhanced inhibitors
WO2010077740A2 (fr) 2008-12-09 2010-07-08 Cytokine Pharmasciences, Inc. Nouveaux composés antiviraux, compositions et procédés d'utilisation
US20120040916A1 (en) 2008-12-22 2012-02-16 Massachusetts Institute Of Technology Molecular inhibitors of the wnt/beta-catenin pathway
WO2010111406A2 (fr) * 2009-03-24 2010-09-30 Myriad Pharmaceuticals, Inc. Composés et leurs utilisations thérapeutiques
WO2010118367A2 (fr) 2009-04-10 2010-10-14 Progenics Pharmaceuticals, Inc. Pyrimidines antivirales
JP5918693B2 (ja) * 2009-05-05 2016-05-18 ダナ ファーバー キャンサー インスティテュート インコーポレイテッド Ｅｇｆｒ阻害剤及び疾患の治療方法
US20110207736A1 (en) 2009-12-23 2011-08-25 Gatekeeper Pharmaceuticals, Inc. Compounds that modulate egfr activity and methods for treating or preventing conditions therewith
WO2011140338A1 (fr) 2010-05-05 2011-11-10 Gatekeeper Pharmaceuticals, Inc. Composés modulant l'activité des récepteurs egfr et méthodes pour traiter ou prévenir des troubles à l'aide de ceux-ci
WO2011163424A2 (fr) 2010-06-22 2011-12-29 University Of Central Florida Research Foundation, Inc. Analogues d'acide 2-(9h-purin-9-yl)acétique substitués en tant qu'inhibiteurs de stat3
WO2012009258A2 (fr) 2010-07-13 2012-01-19 Edward Roberts Modulateurs des récepteurs à la galanine peptidomimétiques
US20120295911A1 (en) 2010-11-29 2012-11-22 Galleon Pharmaceuticals, Inc. Novel Compounds and Compositions for Treatment of Breathing Control Disorders or Diseases
AU2011336764B2 (en) 2010-11-29 2017-02-23 Galleon Pharmaceuticals, Inc. Novel compounds as respiratory stimulants for treatment of breathing control disorders or diseases
CN103874699A (zh) * 2011-09-20 2014-06-18 赛尔佐姆有限公司 吡唑并[4,3-c]吡啶衍生物作为激酶抑制剂
US9881309B2 (en) 2012-03-13 2018-01-30 American Express Travel Related Services Company, Inc. Systems and methods for tailoring marketing
SG11201506531WA (en) 2013-03-14 2015-09-29 Pfizer Combination of an egfr t790m inhibitor and an egfr inhibitor for the treatment of non-small cell lung cancer
US10884952B2 (en) 2016-09-30 2021-01-05 Intel Corporation Enforcing memory operand types using protection keys
JP6943759B2 (ja) 2017-12-28 2021-10-06 株式会社東海理化電機製作所 シフト装置

Also Published As

Publication number Publication date
EA201490673A1 (ru) 2014-06-30
CL2014002726A1 (es) 2015-02-13
MX2014003501A (es) 2014-07-22
CL2014000566A1 (es) 2014-10-10
ES2575710T3 (es) 2016-06-30
MD20140023A2 (ro) 2014-06-30
TWI492946B (zh) 2015-07-21
US9040547B2 (en) 2015-05-26
AU2012311184A1 (en) 2014-03-06
EP2758402A1 (fr) 2014-07-30
CR20140132A (es) 2014-05-16
CO6910196A2 (es) 2014-03-31
ES2575710T9 (es) 2016-10-17
AR088760A1 (es) 2014-07-02
BR112014006840A2 (pt) 2017-04-04
IL231592A0 (en) 2014-05-28
EP2758402B1 (fr) 2016-04-27
PE20141228A1 (es) 2014-10-01
US20130079324A1 (en) 2013-03-28
AP2014007475A0 (en) 2014-02-28
JP5914667B2 (ja) 2016-05-11
US20150203502A1 (en) 2015-07-23
WO2013042006A1 (fr) 2013-03-28
SG2014014450A (en) 2014-09-26
JP2014526549A (ja) 2014-10-06
KR20140059246A (ko) 2014-05-15
EP2758402B9 (fr) 2016-09-14
CN103814030A (zh) 2014-05-21
CA2847540C (fr) 2016-05-17
NI201400023A (es) 2014-10-01
TW201313723A (zh) 2013-04-01
TN2014000115A1 (fr) 2015-07-01
UY34342A (es) 2013-04-30
DOP2014000055A (es) 2014-05-15
CA2847540A1 (fr) 2013-03-28
UA110259C2 (uk) 2015-12-10

Similar Documents

Publication Publication Date Title
MA35451B1 (fr) Dérivés de pyrrolopyrimidine et de purine
MA35841B1 (fr) Dérivés de pyrazolopyridine, procédé d&#39;élaboration de ces dérivés, et utilisation thérapeutique de ceux-ci
RS54207B1 (en) CONDENSED IMIDAZOLYLIMIDAZOLES AS ANTIVIRAL COMPOUNDS
PH12015501412A1 (en) SUBSTITUTED SPIROPYRIDO[1,2-a]PYRAZINE DERIVATIVE AND MEDICINAL USE THEREOF AS HIV INTEGRASE INHIBITOR
RS54386B1 (en) ANTIVIRAL UNITS
EA201100969A1 (ru) Солевые формы органического соединения
EA201070786A1 (ru) Бензофуропиримидиноны
MA34644B1 (fr) Dérivés de pyrazole aminopyrimidine en tant que modulateurs du lrrk2
EA201790923A1 (ru) Производные бетулина
RS53382B (en) PIROL [2,3-D] PIRIMIDINE COMPOUNDS
MA37400B1 (fr) Composés hétérocyclyle en tant qu&#39;inhibiteurs de mek
MA37142A3 (fr) Dérivés de dihydro-benzo-oxazine et de dihydro-pyrido-oxazine
RS53574B1 (en) PYROLOPYRIMIDINE COMPOUNDS AS CDK INHIBITORS
RS53003B (en) C7-FLUORO SUBSTITUTED TETRACYCLINE UNITS
MA34819B1 (fr) Dérivés bicyclo[3.2.1]octylamide et leurs utilisations
BRPI0821255A2 (pt) Derivados de espiroindolinona
MA35749B1 (fr) Dérivés nucléosidiques 4&#39;-azido, 3&#39;-fluoro substitués en tant qu&#39;inhibiteurs de la réplication de l&#39;arn du vhc
MY195209A (en) Partially Saturated Nitrogen-Containing Heterocyclic Compound
MX2010013682A (es) Derivados de 2,4-diamino-l,3,5-triazina triciclicos utiles para el tratamiento del cancer y trastornos mieloproliferativos.
MX2010003603A (es) Metodo para el tratamiento de enfermedades de riñon poliquisticas con derivados de ceramida.
CR10206A (es) Acidos4-fenil-tiazol-5-carboxilicos amidas de acidos 4-fenil-tiazol-5-carboxilicos como inhibidores de la plk1
IN2012DN00765A (fr)
CA2817362C (fr) Composes lipoyles et leur utilisation pour le traitement d&#39;une lesion ischemique
TR201902057T4 (tr) Tetrasiklin bileşikleri.
UY32055A (es) Derivados sustituidos de la 5-Halo-N2-[sustituido](1-metil-1H-imidazol-4-il)pirimidin-2,-diamina y sus sales farmacéuticamente aceptables, procesos de preparación, composiciones y aplicaciones.